trending Market Intelligence /marketintelligence/en/news-insights/trending/XM1X8qnQI71Z3PCx4dhmiA2 content esgSubNav
In This List

Ampersand Capital Partners recapitalizes New England Peptide

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Podcast

Street Talk Episode 87

Blog

A New Dawn for European Bank M&A Top 5 Trends

Blog

Insight Weekly: US banks' loan growth; record share buybacks; utility M&A outlook


Ampersand Capital Partners recapitalizes New England Peptide

Ampersand Capital Partners, which invests in healthcare companies in the middle market, closed a majority recapitalization of New England Peptide Inc.

The Gardner, Mass.-headquartered company designs and manufactures peptide and antibody solutions for drug, vaccine and diagnostic development organizations across the globe.

José de Chastonay, who most recently was chief marketing officer and corporate executive committee member at Bachem Holding AG, joined New England Peptide's board as executive chairman.